Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China

  title={Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China},
  author={Lin Zhang and Bo Hao and Zhihua Geng and Qing Geng},
  journal={Frontiers in Immunology},
Toripalimab (Tuoyi™) is a selective, recombinant, humanized monoclonal antibody against programmed death protein 1 (PD-1) developed by Shanghai Junshi Bioscience Co., Ltd. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. The binding of toripalimab to PD-1 is mainly attributed to the heavy chain of the former and the FG loop of the latter. Toripalimab received a conditional approval in China for the treatment of melanoma (second-line) in December, 2018. It has also… 
2 Citations

Figures and Tables from this paper

Generation, secretion and degradation of cancer immunotherapy target PD-L1.
The regulators that are involved in controlling PD-L1 expression including post-translational modification, mRNA level regulation as well as degradation and exosome secretory pathway of PD- L1 were focused.
Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
This overview provides a comprehensive update on the evolution status of all available OVs in melanoma and non-melanoma skin cancers and summarizes the more interesting preclinical findings, the latest clinical evidence, and the future insights in relation to the expected selective incorporation of some of these OVs into oncological practice.


Toripalimab: First Global Approval
The milestones in the development of toripalimab leading to this first global approval for the treatment of unresectable or metastatic melanoma are summarized.
Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
The analysis reveals that toripalimab mainly binds to the FG loop of PD-1 with an unconventionally long complementarity-determining region 3 loop of the heavy chain, which is distinct from the known binding epitopes of anti-PD-1 mAbs with structural evidences.
Toripalimab for the treatment of melanoma
A number of studies have confirmed that PD-1 inhibitors, including toripalimab, are not as effective in mucosal and acral melanomas as in non-acral cutaneous subtype, and it is crucial to explore the mechanisms underlying the varying biological behavior of melanoma subtypes.
Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer
Regorafenib combined with toripalimab has a promising effect in the third-line and beyond treatment of advanced colorectal cancer.
A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer.
Vorolanib with toripalimab showed a promising antitumor activity with acceptable safety profiles for patients with NSCLC, and the potential benefits of combination therapy for Patients with squamous cell carcinoma may be better than those for patientswith adenocarcinoma.
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer
In this phase 1 trial that enrolled 41 patients with advanced non–small cell lung cancer, toripalimab exhibited encouraging antitumor activity and manageable safety, and JS311 was highly consistent with previously verified PD-L1 assays.
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes, leading to the initiation of the first prospective anti-PD-1 registration trial in Asia.
A phase 1b clinical trial of anti-PD-1 ab (Toripalimab) plus intralesional injection of OrienX010 in stage melanoma with liver metastases.
Systemic toripalimab combined with intrahepatic OrienX010 injection has shown remarkable pathological responses with good tolerance in melanoma liver metastases.
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
  • X. ShengXieqiao Yan Jun Guo
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2019
The combination of toripalimab plus axitinib was tolerable and showed promising antitumor activity in patients with treatment-naïve metastatic mucosal melanoma, and this combination therapy must be validated in a randomized phase III trial that includes a non-Asian population before it can become a standard of care.